Rhabdomyolysis Caused by a Potential Sitagliptin‐Lovastatin Interaction

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pharmacotherapy

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.29.3.352PMID 19249953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Standards of medical care in diabetes--2007.

  2009cited by this paper
• Sitagliptin: A Novel Drug for the Treatment of Type 2 Diabetes

  2007influential reference
• Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism.

  2007cited by this paper
• Proposal for a New Tool to Evaluate Drug Interaction Cases

  2007cited by this paper
• Sitagliptin

  2007cited by this paper
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006influential reference
• The effect of corticosteroid injection for trigger finger on blood glucose level in diabetic patients.

  2006cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Rhabdomyolysis due to hypothyroidism.

  2005cited by this paper
• Outcomes in 45 patients with statin-associated myopathy.

  2005cited by this paper
• Exertional Rhabdomyolysis

  2004cited by this paper
• Potentially fatal interaction between diltiazem and statins.

  2004cited by this paper
• Rhabdomyolysis in a patient with hypothyroidism.

  2003cited by this paper
• High-dose simvastatin and rhabdomyolysis.

  2003cited by this paper
• Rhabdomyolysis and HMG-CoA Reductase Inhibitors

  2001cited by this paper
• Rhabdomyolysis following spinal cord injury: case report.

  1995cited by this paper

• Rhabdomyolysis triggered by initiation of tirzepatide

  2025cites this paper
• Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

  2024cites this paper
• Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report

  2024cites this paper
• Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients

  2023cites this paper
• Case Report: Rhabdomyolysis secondary to vildagliptin overdose in a suicidal attempt: A case report and brief literature review

  2022cites this paper
• Prevalence and predictors of clinically significant statin–drug interactions among Yemeni patients taking statins for primary and secondary prevention of cardiovascular disease

  2022cites this paper
• A Disproportionality Analysis of the Risk of Rhabdomyolysis Associated with DPP-4 Inhibitors in the Food and Drug Administration Adverse Event Reporting System

  2021cites this paper
• DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Pharmacokinetic Aspects of Statins

  2020cites this paper
• Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump

  2019cites this paper
• Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine

  2019cites this paper
• Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system

  2019cites this paper
• Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI

  2019cites this paper
• Diabetes pharmacotherapy and effects on the musculoskeletal system

  2018cites this paper
• Improving Prediction of Systemic Statin Exposure Using Concomitant Medications, Non-Linear Modelling and Novel SNP Discovery

  2018cites this paper
• INTERACCIONES FARMACOLÓGICAS DE ESTATINAS CON AGENTES ANTIDIABÉTICOS NO INSULÍNICOS

  2018cites this paper
• Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels

  2017cites this paper
• The blood lipid regulation of Monascus-produced monascin and ankaflavin via the suppression of low-density lipoprotein cholesterol assembly and stimulation of apolipoprotein A1 expression in the liver.

  2016cites this paper
• Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction

  2016cites this paper
• Does Myocardial Necrosis Occur in Rhabdomyolysis?

  2016cites this paper
• The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

  2014cites this paper
• Association of musculoskeletal complaints and gliptin use: review of spontaneous reports

  2013cites this paper
• Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers

  2013cites this paper
• Interacciones medicamentosas de agentes hipolipemiantes: aproximación para establecer y valorar su relevancia clínica. Revisión estructurada

  2013cites this paper
• Cyclosporine A and lovastatin: the good and the bad, but who will be the winner?

  2013cites this paper
• Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

  2012cites this paper
• Rhabdomyolysis precipitated by a sitagliptin–atorvastatin drug interaction

  2012cites this paper
• Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

  2012cites this paper
• Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

  2012cites this paper
• Glucose-lowering interventions and risk assessment in patients with coronary heart disease and disturbed glucose metabolism

  2012cites this paper
• Creatine kinase elevation, lactacidemia, and metabolic myopathy in adult patients with diabetes mellitus.

  2012cites this paper
• Simvastatin‐induced myopathy, the role of interaction with diltiazem and genetic predisposition

  2011cites this paper
• Sitagliptyna — nowoczesny lek w terapii cukrzycy typu 2

  2011cites this paper
• Sitagliptin: a review

  2011cites this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cites this paper
• Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

  2010cites this paper
• Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2010cites this paper
• Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus Nonpharmacist Clinicians in an Internal Medicine Department of a Private Physician-Owned Multispecialty Clinic

  2009cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2009cites this paper
• Drug Use Evaluation of Sitagliptin Dosing by Pharmacist Versus

  2009cites this paper